Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRV NASDAQ:LVTX NASDAQ:OTLK NASDAQ:PHXM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.52-1.9%$1.36$1.05▼$10.00$48.76M1.663.36 million shs875,976 shsLVTXLAVA Therapeutics$1.55+0.3%$1.49$0.85▼$2.09$40.51M0.5108,930 shs57,150 shsOTLKOncobiologics$1.04-4.6%$1.89$0.79▼$6.98$48.42M0.487.97 million shs5.52 million shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics-1.94%+14.29%+16.03%+26.67%-84.00%LVTXLAVA Therapeutics+0.32%-1.59%+0.98%+17.94%-11.21%OTLKOncobiologics-4.59%+11.23%-51.17%-42.86%-85.21%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.52-1.9%$1.36$1.05▼$10.00$48.76M1.663.36 million shs875,976 shsLVTXLAVA Therapeutics$1.55+0.3%$1.49$0.85▼$2.09$40.51M0.5108,930 shs57,150 shsOTLKOncobiologics$1.04-4.6%$1.89$0.79▼$6.98$48.42M0.487.97 million shs5.52 million shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics-1.94%+14.29%+16.03%+26.67%-84.00%LVTXLAVA Therapeutics+0.32%-1.59%+0.98%+17.94%-11.21%OTLKOncobiologics-4.59%+11.23%-51.17%-42.86%-85.21%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$15.50919.74% UpsideLVTXLAVA Therapeutics 2.00Hold$2.6973.79% UpsideOTLKOncobiologics 2.33Hold$9.60823.08% UpsidePHXMPHAXIAM Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PHXM, ACRV, OTLK, and LVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025OTLKOncobiologicsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral8/28/2025OTLKOncobiologicsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$3.008/28/2025OTLKOncobiologicsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral8/27/2025OTLKOncobiologicsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025OTLKOncobiologicsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$3.008/14/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$9.00 ➝ $8.008/5/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$1.50 ➝ $1.248/5/2025LVTXLAVA TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$3.00 ➝ $1.50(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.68 per shareN/ALVTXLAVA Therapeutics$11.98M3.39N/AN/A$1.06 per share1.46OTLKOncobiologics$1.51M30.69N/AN/A($3.09) per share-0.34PHXMPHAXIAM TherapeuticsN/AN/AN/AN/A$7.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$80.56M-$2.25N/AN/AN/AN/A-50.78%-46.08%11/12/2025 (Estimated)LVTXLAVA Therapeutics-$25.11M-$1.05N/AN/AN/AN/A-106.29%-38.24%N/AOTLKOncobiologics-$75.37M-$0.57N/AN/AN/AN/AN/A-332.30%N/APHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ALatest PHXM, ACRV, OTLK, and LVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q3 2025OTLKOncobiologics-$0.42-$0.44-$0.02-$0.55$1.66 million$1.51 million8/13/2025Q2 2025ACRVAcrivon Therapeutics-$0.57-$0.55+$0.02-$0.55N/AN/A8/13/2025Q2 2025LVTXLAVA Therapeutics-$0.28-$0.32-$0.04-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/AOTLKOncobiologicsN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A10.3110.31LVTXLAVA TherapeuticsN/A10.7810.78OTLKOncobiologicsN/A0.670.54PHXMPHAXIAM Therapeutics0.231.78N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%LVTXLAVA TherapeuticsN/AOTLKOncobiologics11.20%PHXMPHAXIAM Therapeutics0.40%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics11.90%LVTXLAVA Therapeutics9.50%OTLKOncobiologics4.80%PHXMPHAXIAM Therapeutics1.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.46 million27.71 millionNot OptionableLVTXLAVA Therapeutics6026.31 million23.81 millionOptionableOTLKOncobiologics2044.42 million42.29 millionOptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataPHXM, ACRV, OTLK, and LVTX HeadlinesRecent News About These CompaniesPHXM.FR | Phaxiam Therapeutics S.A. Annual Income Statement - WSJJuly 18, 2025 | wsj.comPhaxiam Therapeutics SA (PHXM) Stock Forums - Investing.comJune 27, 2025 | investing.comPHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until DelistingJune 18, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces Judicial Liquidation and DelistingJune 13, 2025 | finance.yahoo.comPHAXIAM Therapeutics: New Postponement of the Offer Review HearingJune 5, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Postponement of the Offer Review HearingMay 23, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Extension of the Observation Period of the Receivership ProcedureMay 5, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Update on the Receivership ProcedureApril 25, 2025 | finance.yahoo.comPhaxiam Therapeutics S.A.March 28, 2025 | wsj.comPHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership ProcedureMarch 15, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results PublicationMarch 6, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Press Release Regarding Suspension of TradingMarch 6, 2025 | finance.yahoo.comPHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage TherapyJanuary 31, 2025 | businesswire.comPHAXIAM Therapeutics Announces Its Financial Calendar for 2025January 13, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in EuropeJanuary 7, 2025 | finance.yahoo.comPHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical StudyDecember 30, 2024 | finance.yahoo.comPHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy areaNovember 27, 2024 | globenewswire.comPHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"November 18, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | finanznachrichten.dePHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHXM, ACRV, OTLK, and LVTX Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.52 -0.03 (-1.94%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.51 -0.01 (-0.66%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.LAVA Therapeutics NASDAQ:LVTX$1.54 +0.01 (+0.32%) Closing price 09/12/2025 03:52 PM EasternExtended Trading$1.54 0.00 (0.00%) As of 09/12/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Oncobiologics NASDAQ:OTLK$1.04 -0.05 (-4.59%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.06 +0.02 (+1.54%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 09/12/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
